everolimus / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 471 Diseases   207 Trials   207 Trials   10577 News 


«12...90919293949596979899100...132133»
  • ||||||||||  everolimus / Generic mfg., sorafenib / Generic mfg.
    Trial primary completion date:  Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas (clinicaltrials.gov) -  Aug 8, 2018   
    P1/2,  N=118, Recruiting, 
    Trial primary completion date: Dec 2018 --> Jul 2019
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial initiation date, Metastases:  Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC) (clinicaltrials.gov) -  Aug 8, 2018   
    P2,  N=13, Not yet recruiting, 
    Trial primary completion date: Dec 2018 --> Jul 2019 Initiation date: Jul 2018 --> Oct 2018
  • ||||||||||  Avastin (bevacizumab) / Roche
    Trial completion date, Trial primary completion date, Metastases:  Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC) (clinicaltrials.gov) -  Aug 2, 2018   
    P2,  N=55, Active, not recruiting, 
    Trial completion date: Jun 2019 --> Jun 2020 | Trial primary completion date: Jun 2018 --> Jun 2019 Trial completion date: Jul 2018 --> Jul 2019 | Trial primary completion date: Jul 2018 --> Jul 2019
  • ||||||||||  everolimus / Generic mfg., sorafenib / Generic mfg.
    Trial completion date, Trial primary completion date:  Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer (clinicaltrials.gov) -  Aug 2, 2018   
    P2,  N=41, Active, not recruiting, 
    Trial completion date: Jul 2017 --> Aug 2018 Trial completion date: Jun 2018 --> Jun 2019 | Trial primary completion date: Jun 2018 --> Jun 2019
  • ||||||||||  cisplatin / Generic mfg., everolimus / Generic mfg.
    Enrollment closed, Trial completion date, Trial primary completion date:  NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer (clinicaltrials.gov) -  Jul 26, 2018   
    P2,  N=23, Active, not recruiting, 
    Recruiting --> Active, not recruiting | N=36 --> 62 | Trial completion date: Oct 2017 --> May 2019 | Trial primary completion date: Oct 2017 --> May 2019 Recruiting --> Active, not recruiting | Trial completion date: Aug 2017 --> Aug 2019 | Trial primary completion date: Aug 2017 --> Jan 2019
  • ||||||||||  everolimus / Generic mfg., sirolimus / Generic mfg.
    Journal:  mTOR kinase inhibition effectively decreases progression of a subset of neuroendocrine tumors that progress on rapalog therapy and delays cardiac impairment. (Pubmed Central) -  Jul 25, 2018   
    Inhibition of mTOR signaling using the rapalog everolimus is an FDA-approved targeted therapy for patients with lung and gastroenteropancreatic neuroendocrine tumors (NET)...We performed preclinical studies using human pNET cells in vitro and injected them subcutaneously or orthotopically to determine tumor progression and cardiac function in mice treated with either rapamycin alone or switched to CC-223 upon progression...Moreover, CC-223 had an additional transient cardiac benefit on valvular fibrosis compared to placebo- or rapalog-treated mice. These results provide the preclinical rationale to further develop mTORKi clinically upon progression on rapalog therapy and to further test their long term cardioprotective benefit in those NET patients prone to carcinoid syndrome.
  • ||||||||||  everolimus / Generic mfg.
    Biomarker, Trial completion, Metastases:  Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma (clinicaltrials.gov) -  Jul 24, 2018   
    P2,  N=40, Completed, 
    These results provide the preclinical rationale to further develop mTORKi clinically upon progression on rapalog therapy and to further test their long term cardioprotective benefit in those NET patients prone to carcinoid syndrome. Active, not recruiting --> Completed
  • ||||||||||  Mekinist (trametinib) / Novartis, BeiGene
    Trial completion, Trial completion date, Trial primary completion date:  GSK1120212 Rollover Study (clinicaltrials.gov) -  Jul 20, 2018   
    P2,  N=250, Completed, 
    Trial primary completion date: Apr 2018 --> Dec 2018 Active, not recruiting --> Completed | Trial completion date: Aug 2018 --> Jan 2018 | Trial primary completion date: Aug 2018 --> Jan 2018
  • ||||||||||  everolimus / Generic mfg.
    Enrollment closed, Trial completion date, Trial primary completion date, Metastases:  MAIN-A: Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients (clinicaltrials.gov) -  Jul 20, 2018   
    P3,  N=253, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Aug 2018 --> Jan 2018 | Trial primary completion date: Aug 2018 --> Jan 2018 Recruiting --> Active, not recruiting | Trial completion date: Dec 2018 --> Jun 2020 | Trial primary completion date: Feb 2018 --> Dec 2019
  • ||||||||||  telaglenastat (CB-839) / Calithera
    Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy, Metastases:  Study of the Glutaminase Inhibitor CB-839 in Solid Tumors (clinicaltrials.gov) -  Jul 19, 2018   
    P1,  N=205, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Dec 2018 --> Jun 2020 | Trial primary completion date: Feb 2018 --> Dec 2019 Recruiting --> Active, not recruiting | Trial completion date: Sep 2017 --> Sep 2019 | Trial primary completion date: Jun 2017 --> Jun 2019
  • ||||||||||  Zokinvy (lonafarnib) / Eiger
    Trial completion date, Trial primary completion date, Combination therapy:  Phase I/II Trial of Everolimus in Combination With Lonafarnib in Progeria (clinicaltrials.gov) -  Jul 18, 2018   
    P1/2,  N=80, Recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Sep 2017 --> Sep 2019 | Trial primary completion date: Jun 2017 --> Jun 2019 Trial completion date: Dec 2019 --> Dec 2021 | Trial primary completion date: Dec 2018 --> Dec 2020
  • ||||||||||  everolimus / Generic mfg.
    Trial completion date, Trial primary completion date:  Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer (clinicaltrials.gov) -  Jul 13, 2018   
    P4,  N=336, Recruiting, 
    Trial completion date: Dec 2019 --> Dec 2021 | Trial primary completion date: Dec 2018 --> Dec 2020 Trial completion date: Oct 2018 --> Aug 2019 | Trial primary completion date: Oct 2018 --> Aug 2019
  • ||||||||||  everolimus / Generic mfg.
    Trial completion date, Trial primary completion date:  Effect of Everolimus on the Pharmacokinetics of Tacrolimus in Renal Transplant Patients (clinicaltrials.gov) -  Jul 11, 2018   
    P4,  N=70, Recruiting, 
    Trial completion date: Apr 2018 --> Jul 2018 | Trial primary completion date: Jun 2017 --> Jul 2018 Trial completion date: Jan 2018 --> Feb 2019 | Trial primary completion date: Jan 2018 --> Feb 2019
  • ||||||||||  cyclophosphamide / Generic mfg., everolimus / Generic mfg., mesna / Generic mfg.
    New P1/2 trial:  LITMMUS-MGH: Liver Transplantation With Tregs at MGH (clinicaltrials.gov) -  Jul 5, 2018   
    P1/2,  N=9, Not yet recruiting, 
  • ||||||||||  everolimus / Generic mfg., sorafenib / Generic mfg.
    Trial primary completion date, Metastases:  Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone (clinicaltrials.gov) -  Jul 2, 2018   
    P2,  N=40, Active, not recruiting, 
    Because the PFS reported for R/E was similar to that reported for everolimus plus exemestane in patients with advanced breast cancer, it is possible that lower-dose ridaforolimus in the R/D/E arm (from overlapping toxicities with IGF1R inhibitor) contributed to lack of improved PFS. Trial primary completion date: Nov 2014 --> Nov 2018
  • ||||||||||  Mycobutin (rifabutin) / Pfizer, Lupin
    Biomarker, Trial completion date, Trial primary completion date:  TBHDT: TB Host Directed Therapy (clinicaltrials.gov) -  Jun 29, 2018   
    P2,  N=200, Recruiting, 
    Trial primary completion date: Nov 2014 --> Nov 2018 Trial completion date: Mar 2018 --> Dec 2020 | Trial primary completion date: Mar 2018 --> Sep 2018
  • ||||||||||  LCL161 / Novartis, spartalizumab (PDR001) / Novartis
    Trial completion date, Trial primary completion date, Combination therapy, PD(L)-1 Biomarker:  A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat (clinicaltrials.gov) -  Jun 18, 2018   
    P1,  N=350, Recruiting, 
    Trial completion date: Feb 2020 --> Apr 2021 | Trial primary completion date: Feb 2020 --> Jul 2019 Trial completion date: May 2019 --> Dec 2019 | Trial primary completion date: May 2019 --> Nov 2019
  • ||||||||||  everolimus / Generic mfg.
    Trial completion date, Trial primary completion date:  EVACEL: Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine Tumors (clinicaltrials.gov) -  Jun 13, 2018   
    P2,  N=74, Active, not recruiting, 
    N=285 --> 397 | Trial completion date: Dec 2020 --> Jan 2022 | Trial primary completion date: Dec 2020 --> Jan 2022 Trial completion date: Apr 2017 --> Apr 2019 | Trial primary completion date: Apr 2017 --> Sep 2018
  • ||||||||||  everolimus / Generic mfg., Sutent (sunitinib) / Pfizer
    Review, Journal:  Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature. (Pubmed Central) -  Jun 9, 2018   
    To further define and clarify the utility, appropriateness, and the sequence of the growing list of available therapies for this patient population will require more high level evidence; however, data from well-designed randomized phase III clinical trials is rapidly accumulating that will further stimulate development of new management strategies. It is therefore important to thoroughly review emerging evidence and report major findings in frequent updates, which will expand our knowledge and contribute to a better understanding, characterization, and management of advanced NETs.
  • ||||||||||  Sutent (sunitinib) / Pfizer
    Trial completion date, Trial primary completion date, Metastases:  Potential Molecular Predictors of Response to Novel Therapies in Metastatic Pancreatic Neuroendocrine Tumors (clinicaltrials.gov) -  Jun 4, 2018   
    P=N/A,  N=30, Recruiting, 
    It is therefore important to thoroughly review emerging evidence and report major findings in frequent updates, which will expand our knowledge and contribute to a better understanding, characterization, and management of advanced NETs. Trial completion date: May 2018 --> May 2019 | Trial primary completion date: May 2018 --> May 2019